Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan
Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Anticancer Res. 2020 Dec;40(12):7135-7140. doi: 10.21873/anticanres.14743.
To clarify the differences in overall survival (OS) depending on the presence or absence of hypomagnesemia and the type of epidermal growth factor receptor antibody as first-line therapy for metastatic colorectal cancer (mCRC).
We retrospectively compared the OS in 68 patients who received cetuximab or panitumumab for mCRC at Ogaki Municipal Hospital (Ogaki, Japan) between January 2010 and December 2019.
The complete and partial response rates in the cetuximab and panitumumab groups were 60.0% and 72.0%, respectively (p=0.470). The OS was significantly longer in the panitumumab group (median=1,007 days, range=208-1,433 days) than in the cetuximab group (median=735 days, range=181-2,391 days; p=0.047). Hypomagnesemia did not contribute to differences in OS in the two groups.
Panitumumab may lead to a longer OS than cetuximab as first-line treatment of mCRC. The presence or absence of hypomagnesemia in cetuximab- or panitumumab-treated patients did not affect OS.
明确转移性结直肠癌（mCRC）患者一线接受西妥昔单抗或帕尼单抗治疗时，低镁血症的有无和表皮生长因子受体抗体类型对总生存期（OS）的影响差异。
我们回顾性比较了 2010 年 1 月至 2019 年 12 月在日本大垣市大垣市民医院接受西妥昔单抗或帕尼单抗治疗的 68 例 mCRC 患者的 OS。
西妥昔单抗组和帕尼单抗组的完全缓解率和部分缓解率分别为 60.0%和 72.0%（p=0.470）。帕尼单抗组的 OS 明显长于西妥昔单抗组（中位 OS=1007 天，范围 208-1433 天）（p=0.047）。两组中低镁血症均未导致 OS 差异。
帕尼单抗作为 mCRC 的一线治疗药物，其 OS 可能长于西妥昔单抗。西妥昔单抗或帕尼单抗治疗患者的低镁血症的有无不影响 OS。
